175 related articles for article (PubMed ID: 27265913)
1. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case.
Marques P; Grossman A
Acta Med Port; 2015; 28(6):775-9. PubMed ID: 27265913
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
[TBL] [Abstract][Full Text] [Related]
4. Hypophysitis and other autoimmune complications related to immune checkpoints inhibitors´ treatment: Spectrum of imaging appearances.
Malikova H; Holesta M; Fialova A; Arenbergerova M; Weichet J
Neuro Endocrinol Lett; 2018 Sep; 39(3):196-204. PubMed ID: 30431741
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
6. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab cystic hypophysitis mimicking metastatic melanoma.
Wallace J; Krupa M; Brennan J; Mihlon F
Radiol Case Rep; 2018 Jun; 13(3):740-742. PubMed ID: 29977435
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab treatment associated pituitary hypophysitis: clinical presentation and imaging diagnosis.
Chodakiewitz Y; Brown S; Boxerman JL; Brody JM; Rogg JM
Clin Neurol Neurosurg; 2014 Oct; 125():125-30. PubMed ID: 25127260
[TBL] [Abstract][Full Text] [Related]
10. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
Faje AT; Lawrence D; Flaherty K; Freedman C; Fadden R; Rubin K; Cohen J; Sullivan RJ
Cancer; 2018 Sep; 124(18):3706-3714. PubMed ID: 29975414
[TBL] [Abstract][Full Text] [Related]
11. Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A; Gupta A; Karavitaki N; Middleton MR; Grossman AB
Eur J Endocrinol; 2012 Jul; 167(1):1-5. PubMed ID: 22495490
[TBL] [Abstract][Full Text] [Related]
12. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic granulomatous hypophysitis presenting with galactorrhea, headache, and nausea in a woman: a case report and review of the literature.
Sharifi G; Mohajeri-Tehrani MR; Navabakhsh B; Larijani B; Valeh T
J Med Case Rep; 2019 Nov; 13(1):334. PubMed ID: 31731892
[TBL] [Abstract][Full Text] [Related]
14. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
[TBL] [Abstract][Full Text] [Related]
15. Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease.
Torino F; Barnabei A; De Vecchis L; Salvatori R; Corsello SM
Oncologist; 2012; 17(4):525-35. PubMed ID: 22477725
[TBL] [Abstract][Full Text] [Related]
16. Ipilimumab-induced hypophysitis: MR imaging findings.
Carpenter KJ; Murtagh RD; Lilienfeld H; Weber J; Murtagh FR
AJNR Am J Neuroradiol; 2009 Oct; 30(9):1751-3. PubMed ID: 19474123
[TBL] [Abstract][Full Text] [Related]
17. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab-induced hypophysitis: review of the literature.
Araujo PB; Coelho MC; Arruda M; Gadelha MR; Neto LV
J Endocrinol Invest; 2015 Nov; 38(11):1159-66. PubMed ID: 25957829
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-induced hypophysitis with transient ACTH-dependent hypercortisolism.
AlRubaish FA; Gupta N; Shi MZ; Christopoulos S
BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772867
[TBL] [Abstract][Full Text] [Related]
20. MRI Findings of Immune Checkpoint Inhibitor-Induced Hypophysitis: Possible Association with Fibrosis.
Kurokawa R; Ota Y; Gonoi W; Hagiwara A; Kurokawa M; Mori H; Maeda E; Amemiya S; Usui Y; Sato N; Nakata Y; Moritani T; Abe O
AJNR Am J Neuroradiol; 2020 Sep; 41(9):1683-1689. PubMed ID: 32763900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
